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OBJECTIVE
Evidence is inconsistent for the association between sulfonylurea use and risk of
cardiovascular disease among patients with diabetes. We aimed to prospectively
evaluate this association using the Nurses’ Health Study (NHS), a well-established
cohort of U.S. women with long-term follow-up.
RESEARCH DESIGN AND METHODS
We followed 4,902 women (mean age 68 years) with diabetes (mean duration 11
years), but without cardiovascular disease at baseline. The use of sulfonylureas
and other medications was self-reported at baseline and during the follow-up
period of up to 10 years. Cox proportional hazards regression models were used
to estimate the relative risk (RR) and 95% CI for the association between the
sulfonylurea use and incident cardiovascular disease while accounting for poten-
tial confounders, including age, diabetes duration, diabetes-related complica-
tions, other antihyperglycemic medications, BMI, lifestyle factors, family history
of cardiovascular diseases, and present chronic conditions. We also applied
the propensity score stratiﬁcation method to address the possibility of residual
confounding.
RESULTS
We identiﬁed 339 incident cases of cardiovascular disease, including 191 cases of
coronary heart disease (CHD) and 148 cases of stroke. A longer duration of sulfo-
nylurea use was signiﬁcantly associated with a higher risk of CHD (P for trend =
0.002); the RRs for CHD were 1.24 (95% CI 0.85–1.81) for patients who used
sulfonylurea therapy for 1–5 years, 1.51 (0.94–2.42) for 6–10 years, and 2.15
(1.31–3.54) for >10 years, compared with nonusers. Compared with users of
metforminmonotherapy, the RR for CHDwas 3.27 (1.31–8.17) for those whowere
treated with the combination of metformin and sulfonylurea. The analysis using
propensity score stratiﬁcation yielded similar results. We did not observe a sig-
niﬁcant association between sulfonylurea therapy and stroke risk.
CONCLUSIONS
Long-term use of sulfonylureas was associated with a signiﬁcantly higher risk of
developing CHD among women with diabetes.
1Department of Nutrition, Harvard School of
Public Health, Boston, MA
2Division of Rheumatology, Immunology, and
Allergy, Brigham and Women’s Hospital and
Harvard Medical School, Boston, MA
3U.S. Outcomes Research, Merck, Whitehouse
Station, NJ
4Department of Epidemiology, Harvard School of
Public Health, Boston, MA
5Channing Division of Network Medicine, Depart-
ment ofMedicine, BrighamandWomen’sHospital,
Harvard Medical School, Boston, MA
Corresponding author: Frank B. Hu, nhbfh@
channing.harvard.edu.
Received 22 May 2014 and accepted 27 July
2014.
© 2014 by the American Diabetes Association.
Readers may use this article as long as the work
is properly cited, the use is educational and not
for proﬁt, and the work is not altered.
Yanping Li,1 Yang Hu,2 Sylvia H. Ley,1
Swapnil Rajpathak,3 and Frank B. Hu1,4,5
3106 Diabetes Care Volume 37, November 2014
C
A
R
D
IO
V
A
SC
U
LA
R
A
N
D
M
ET
A
B
O
LI
C
R
IS
K
Cardiovascular disease is a highly prev-
alent complication of type 2 diabetes
that accounts for 50–80% of the deaths
among patients with diabetes (1).
Therefore, prevention of cardiovascular
morbidity and mortality is an important
goal for diabetes treatment. Sulfonylureas
are one of the effective antihyperglyce-
mic agents recommended by the Amer-
ican Diabetes Association (2). Although
sulfonylureas have been a mainstay of
type 2 diabetes pharmacotherapy for
many years, the potential adverse ef-
fects of sulfonylureas have been raised
by previous studies (3–5). Currently ap-
proved package labels for all sulfonyl-
ureas bear a warning for increased
cardiovascular risk (6,7). Concerns about
the cardiovascular safety of sulfonyl-
ureas date back to the 1970s, when the
University Group Diabetes Program
(UGDP) clinical trial (4) was terminated
prematurely because of the excess car-
diovascular mortality in the group pre-
scribed tolbutamide, a ﬁrst generation
sulfonylurea.
The UGDP results have been debated
concerning the study’s nonrandomized
design and low statistical power to test
the hypothesis of inferior cardiovascular
safety for sulfonylureas versus placebo.
However, the lack of beneﬁcial effects of
sulfonylureas on the incidence of car-
diovascular events was observed in the
UK Prospective Diabetes Study (UKPDS)
(8). A meta-analysis of clinical trials
demonstrated a lack of evidence for car-
diovascular beneﬁt and an increased
mortality risk in patients with diabetes
using sulfonylureas (5). In addition, the
combination treatment with metformin
and sulfonylurea, which are the two
most commonly used drugs for glycemic
control, has been associated with a
higher risk of total mortality in several
(9–13), but not all, studies (14). Recently,
an increased risk of cardiovascular events
or death was documented in several ob-
servational studies; however, those stud-
ies were mainly retrospective studies
(15,16), lacked adjustment for important
confounding factors (17,18), had a short
period of follow-up (19), or were based
on the health administrative data without
conﬁrmation of cardiovascular outcomes
(15,18,19). Thus, the purpose of the cur-
rent study was to prospectively evaluate
the association between long-term use of
sulfonylureas and incident cardiovascular
disease among patients with diabetes but
without amedical historyof cardiovascular
disease at baseline within an ongoing well-
established cohort, the Nurses’ Health
Study (NHS) (20).
RESEARCH DESIGN AND METHODS
Study Population
The NHS cohort was established in
1976 when 121,700 female regis-
tered nurses aged 30 to 55 years and
residing in 11 U.S. states completed a
mailed questionnaire on their medical
history and lifestyle characteristics (20).
Every 2 years, follow-up questionnaires
have been sent to update information
on potential risk factors and to identify
newly diagnosed cases of type 2 diabetes
and cardiovascular and other medical
events.
In 2000 and 2005, 5,536 patients with
type 2 diabetes responded to the sup-
plemental questionnaires regarding
their diabetes treatment and diabetes-
related complications. Participants with
prevalent cardiovascular disease (n = 634)
at the time of supplemental question-
naire collections were excluded from
the analysis. Thus, 4,902 participants
were included in the current study inves-
tigating incident cardiovascular disease.
The end of the follow-up period was 30
June 2010.
The institutional review boards at the
Harvard School of Public Health and
Brigham and Women’s Hospital ap-
proved the study protocol.
Ascertainment of Type 2 Diabetes
Type 2 diabetes was ascertained by self-
reported cases conﬁrmed using a vali-
dated supplementary questionnaire
(21). We used the National Diabetes
Data Group criteria to deﬁne type 2 di-
abetes for the cases before 1998 and the
American Diabetes Association diagnostic
criteria from 1998 onward.
The validation of self-reported type 2
diabetes diagnosis in the NHS has been
documented previously. In a random sam-
ple of 62 cases inNHS thatwere conﬁrmed
by the supplementary questionnaire, 61
cases (98%) were reconﬁrmed after med-
ical record review by an endocrinologist
blinded to the supplementary question-
naire (21). In a random sample of partic-
ipants (n = 200)who reported no diabetes,
only one participant (0.5%) had an ele-
vated fasting plasma glucose in the dia-
betic range, and with levels that were
barely above the diagnostic cutoffs.
Assessment of Cardiovascular Events
and Mortality
We included nonfatal myocardial infarc-
tion, coronary heart disease (CHD)
death, and stroke in our end point of
cardiovascular disease, which was iden-
tiﬁed primarily through a review ofmed-
ical records, as previously described
(22). We requested permission to re-
view medical records when a woman
reported a nonfatal CHD or stroke. We
also sought medical records for de-
ceased participants, whose deaths
were identiﬁed by families and postal
ofﬁcials and through the National Death
Index. Physicians blinded to the partici-
pant questionnaire reports reviewed all
medical records.
Nonfatal myocardial infarction was
conﬁrmed if the criteria of the World
Health Organization were met, speciﬁ-
cally, on the basis of symptoms and ei-
ther electrocardiographic changes or
elevated cardiac enzyme concentra-
tions. Stroke was conﬁrmed by medical
records according to the criteria of the
National Survey of Stroke, requiring evi-
dence of a neurologic deﬁcit with sudden
or rapid onset that persisted for.24 h or
until death. All strokes since 1976 were
reviewed by a neurologist and classiﬁed
according to the criteria used in the Perth
Community Stroke Study by stroke sub-
type and/or etiology: subarachnoid hem-
orrhage, intraparenchymal hemorrhage,
ischemic stroke (thrombotic or embolic),
or stroke of unknown causes.
Deaths were reported by next of kin
and the postal system and through re-
cords of the National Death Index. Using
all sources combined, we estimated that
follow-up for death was over 98% com-
plete. Fatal CHD was deﬁned as fatal
myocardial infarction if this was con-
ﬁrmed by hospital records or autopsy,
or if CHDwas listed as the cause of death
on the certiﬁcate and this was the un-
derlying and only plausible cause, and
evidence of previous CHD was available
(22). Fatal strokes were coded using the
same criteria as for nonfatal cases, but
autopsy evidence was also accepted as
was a death certiﬁcate listing the cause
of death as stroke.
Assessment of Diabetes Treatments
and Complications
A supplementary questionnaire on dia-
betes therapy and complications was
administered in the NHS in years 2000
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and 2005. This questionnaire was based
on the one used in the National Health In-
terview Survey designed by Dr. Maureen
Harris and colleagues (23,24). It asked
about diagnosis of the disease, general
medical care, frequency of clinical visits,
symptoms of diabetes-related complica-
tions, glucose monitoring, and diabetes
treatment. Diabetes-related complica-
tions included diabetic retinal diseases,
diabetic kidney diseases, and diabetic
brain damage. In the supplemental ques-
tionnaires, we asked patients with diabe-
tes about their medication use, including
metformin, troglitazone, acarbose, insu-
lin, and other diabetic medications, as
well as sulfonylureas (e.g., Micronase,
Glucotrol, Tolinase, or Diabinese).We in-
quired about the total duration of each
medication use.
Information on microvascular compli-
cations, including retinopathy and ne-
phropathy, was collected. Duration of
diabetes was assessed by asking partic-
ipants when they were ﬁrst diagnosed
with diabetes in both the biennial and
supplementary questionnaires.
Assessment of Covariates
Information on potential confounders,
including age, body weight, smoking
status, physical activity, useof aspirin,mul-
tiple vitamin supplements, cholesterol-
lowering medications, antidepressants,
and antihypertensive medications,
and a history of major chronic condi-
tions, including hypertension, hypercho-
lesterolemia, cancer, and coronary
artery bypass graft, was collected via
the regular biennial questionnaires
throughout the follow-up of NHS (infor-
mation of confounders for current anal-
ysis was repeatedly collected at 2000,
2002, 2004, 2006, and 2008 cycles).
BMI was calculated as weight in kilo-
grams divided by height in meters
squared from self-reported weight and
height. Starting in 1980, on a 2–4-year
cycle, dietary information has been up-
dated using validated semiquantitative
food frequency questionnaires. We gen-
erated an alternative healthy eating in-
dex score to evaluate the diet quality,
which has been signiﬁcantly associated
with cardiovascular disease in our cohort
(25). Alcohol use was assessed by the
food frequency questionnaires, which in-
cluded questions about average daily
consumption of beer, wine, and spirits
during the previous year.
Statistical Analysis
Among those 4,902 participants for cur-
rent analysis, 1,367 (28%) only responded
to the 2000 supplemental questionnaire
and 2,578 (52%) responded to both 2000
and 2005 supplemental questionnaires
(2000 cycle was treated as their baseline
survey). Another 957 (20%) participants
only enrolled in the 2005 cycle,whichwas
treated as their baseline survey. Individu-
als contributed to person-time from the
return of the baseline questionnaire until
the date of diagnosis of cardiovascular
disease, death, loss to follow-up, or the
end of the follow-up period (30 June
2010), whichever came ﬁrst.
Weexamined the risk of cardiovascular
disease according to the duration of
sulfonylurea use (1–5, 6–10, and .10
years) versus a nonuser of sulfonylureas.
Participants reporting having used sulfo-
nylureas before baseline but not report-
ing use of sulfonylureas at baseline or
during the follow-up period were classi-
ﬁed into the category of nonusers. In a
secondary analysis, participants were
classiﬁed into mutually exclusive catego-
ries according to their medication use:
metformin alone (reference group), sul-
fonylurea alone, combination of sulfo-
nylurea and metformin, nonuse of
antihyperglycemic medications, insulin
only, and other combinations of diabetic
medications.
We used multivariable Cox propor-
tional hazards models to estimate haz-
ard ratios as estimates of the relative
risk (RR) and 95% CI comparing sulfonyl-
urea users with nonusers. To quantify a
linear trend of duration of sulfonylurea
use, we conducted aWald test for linear
trend by assigning the median value to
each category of duration of sulfonyl-
urea use and modeling this variable
as a continuous variable.
Model 1 was an age-adjusted model
(age in months). Multivariable model 2
further adjusted BMI (kg/m2); physical
activity (quintiles); smoking status (nev-
er smoker, former smoker, or current
smoker: 1–14 or$15 cigarettes/day); al-
cohol drinking (0, 0.1–9.9, 10.0–19.9,
20.0–29.9, and $30 g/day); alternative
healthy eating index as a marker of overall
diet quality (quintile); ethnicity (Caucasian,
yes/no); familyhistoryofmyocardial infarc-
tion (yes/no); family history of stroke (yes/
no); use of aspirin,multiple vitamin supple-
ments, cholesterol-lowering medications,
antidepressants, and antihypertensive
medications; and ahistory ofmajor chronic
conditions, including hypertension, hy-
percholesterolemia, cancer, and coronary
artery bypass graft (each yes/no). All
covariates, except for family history of
myocardial infarction, were updated
during follow-up and included as time-
varying covariates in the models.
Multivariable model 3 further adjusted
for diabetes-related complications and
other diabetic medications, e.g., plasma
HbA1c (missing and ,7, 7–7.9, 8–9.9,
10–11.9, and $12); duration of diabetes
affecting the back of eyes (retina: not af-
fected and,2, 2–5, and.6 years); dura-
tion of diabetes-related kidney disease
(not affected and,2, 2–5, and.6 years);
duration of diabetes-related neuropathy
(nerve damage: not affected and,2, 2–5,
6–9, 10–14, and $15 years); and use of
other diabetic medications, including in-
sulin, rosiglitazone, pioglitazone, acar-
bose, and other diabetic medications
(past, never, and current users for each).
In multivariable model 4, we further ad-
justed for the duration of diabetes.
To address the possibility of residual
confounding, we also applied the pro-
pensity score stratiﬁcation method.
The propensity score was the estimated
probability of treatment selection con-
ditional on observed covariates (26),
which was calculated for each treat-
ment method as dependent variable re-
spectively and all the covariates listed
above (from model 1 to 3) as indepen-
dent variables. Quintiles of the propen-
sity scores of different treatments and
untreated subjects were included in the
analysis. The effect of treatment on out-
comeswas estimatedwithin each stratum
of the propensity score. Stratum-speciﬁc
treatment effects were then pooled to
obtain an overall treatment effect (26,27).
We examined potential interactions
of the sulfonylurea use with presence
of hypertension, hypercholesterolemia,
or diabetic kidney disease on risk of car-
diovascular disease as well as CHD and
stroke by including a multiplicative term
in the Cox model with adjustment for
other potential confounders.
To test the robustness of our ﬁndings
between sulfonylureas and cardiovascu-
lar disease, we conducted two sensitiv-
ity analyses. In the ﬁrst sensitivity
analysis, we excluded the participants
reporting having used sulfonylureas be-
fore baseline but not reporting use of
sulfonylureas at baseline or during the
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follow-up period from the category of
nonusers. In the second sensitivity analy-
sis, we limited our analysis to the partici-
pants who responded to the diabetes
supplemental questionnaire in both 2000
and 2005 and classiﬁed the participants as
nonusers, no-consistent users, and con-
sistent users who reported using of sul-
fonylureas in both 2000 and 2005 cycles.
Data were analyzed using a commer-
cially available softwareprogram (SAS, ver-
sion 9.3; SAS Institute, Inc.), and statistical
signiﬁcance was set at a two-tailed,0.05.
RESULTS
We collected the sulfonylurea therapy
information from 4,902 diabetic nurses
without diagnosis of cardiovascular dis-
ease at baseline, including 2,467 nonus-
ers and 2,435 users during the follow-up
period of 2000–2010. At baseline, the
mean age of the nurses was 68 years
with an average duration of diabetes
of 11 years. As shown in Table 1, sulfo-
nylurea therapy was associated with
longer duration of diabetes, diabetes-
related complications, and use of other
antihyperglycemic medications. The prev-
alence of smoking, multivitamin use, aspi-
rin use, use of antidepressantmedications,
family history of cardiovascular diseases,
and presence of hypertension at baseline
were similar across categories of sulfonyl-
urea therapy (Table 1).
During 5–10 years of follow-up, we
identiﬁed 339 incident cases of cardio-
vascular disease, including 191 cases of
CHD (145 nonfatal myocardial infarction
and 46 CHD deaths) and 148 cases of
stroke. Compared with nonusers of
sulfonylurea, the multivariable-adjusted
RRs of total cardiovascular diseases for
patientswith diabeteswhohadbeenusing
sulfonylurea therapy for 1–5, 6–10, and
.10 years were 1.20 (95% CI 0.91–1.58),
1.40 (0.98–1.99) and 1.65 (1.12–2.43),
respectively (Table 2). However, when
we examined the association of sulfony-
lureas with CHD and stroke separately,
increasing the duration of sulfonylurea
use was only signiﬁcantly associated
with CHD risk (P for trends = 0.005)
(Table 2). The multivariable-adjusted
RRs for CHD were 1.24 (0.85–1.81) for
patients who had used sulfonylurea
therapy for 1–5 years, 1.51 (0.94–2.42)
for 6–10 years, and 2.15 (1.31–3.54) for
.10 years compared with nonusers. We
did not ﬁnd a signiﬁcant association be-
tween the duration of sulfonylurea use
and risk of stroke (Table 2). As compared
with metformin monotherapy, the mul-
tivariable RR of combination therapy
with metformin and sulfonylurea for to-
tal cardiovascular disease was 1.99
(1.07–3.70), which was 3.27 (1.31–8.17)
for CHD and 1.10 (0.45–2.69) for stroke
(Table 3).
The analysis using propensity score
stratiﬁcation yielded similar results.
The multivariable-adjusted RRs for CHD
were 1.15 (95% CI 0.79–1.68) for pa-
tients who had used sulfonylurea ther-
apy for 1–5 years, 1.39 (0.87–2.23) for
6–10 years, and 1.99 (1.22–3.25) for
.10 years compared with nonusers by
the stratiﬁcation of propensity score
method (P for trend = 0.005). As com-
pared with metformin monotherapy,
the multivariable RR of combination
therapy with metformin and sulfonyl-
urea for CHD was 3.10 (1.21–7.94).
The interactions between sulfonylurea
use and presence of chronic conditions (hy-
pertension, hypercholesterolemia, and dia-
betic kidney disease) were not signiﬁcant
on risk of cardiovascular disease, CHD, or
stroke (P for interaction.0.1 for all). After
we excluded past users (i.e., the partici-
pants reporting having used sulfonylureas
beforebutnot reportinguseof sulfonylurea
during the follow-up period) from the
category of nonusers, the multivariable-
adjusted RR for CHD was 2.17 (95% CI
1.27–3.71; P for trends = 0.004) for partic-
ipants who had used sulfonylureas for 10
more years as compared with never users.
In the second sensitivity analysis among
participantswho responded to thediabetes
supplementary questionnaire in both 2000
Table 1—Basic characteristics of subjects at baseline according to current use of
sulfonylurea
Duration of sulfonylurea (years)
None 1–5 6–10 .10 P for trends**
n (total = 4,902) 2,467 1,601 532 302
Age* (years) 68.8 67.5 67.6 68.6 0.006
BMI (kg/m2) 30.3 31.3 31.6 31.0 0.0002
Energy intake (kcal/day) 1,613 1,648 1,579 1,649 0.8
Alcohol (g/day) 2.4 1.6 1.5 1.6 0.0008
Physical activity (h/week) 1.0 0.9 0.9 0.6 0.003
Alternative healthy eating index score 52.1 51.0 50.7 50.3 0.0003
Current smoking (%) 7.0 7.3 7.6 5.6 0.7
Multivitamin use (%) 67.9 64.9 67.6 62.6 0.1
Family history of myocardial infarction (%) 27.3 14.0 14.1 12.4 0.98
Family history of stroke (%) 7.1 7.5 6.1 8.9 0.6
Diabetic characteristics and medications
Diabetes duration (years) 10.5 11.4 12.4 17.2 ,0.0001
HbA1c (%) 7.0 7.6 7.7 7.8 ,0.0001
Diabetic retina (%) 13.6 19.5 17.6 26.0 ,0.0001
Diabetic kidney disease (%) 2.8 3.3 3.7 7.5 0.0004
Diabetic neuropathy (%) 17.6 24.3 25.9 32.1 ,0.0001
Insulin (%) 16.4 28.4 22.5 23.7 ,0.0001
Rosiglitazone (%) 8.9 12.5 14.7 15.5 ,0.0001
Pioglitazone (%) 6.4 10.5 7.4 12.9 0.001
Acarbose (%) 3.1 2.1 2.6 1.3 0.08
Other combinations of medications (%) 15.8 10.0 4.9 6.7 ,0.0001
History of other chronic conditions and medications
Hypertension (%) 57.8 57.8 57.3 58.3 0.7
Hypercholesterolemia (%) 51.3 48.8 47.8 43.8 0.01
Cancer (%) 16.5 19.1 20.8 20.1 0.007
Aspirin (%) 52.6 51.2 51.1 50.2 0.3
Antihypertensive medications (%) 63.0 65.1 68.7 63.1 0.09
Antidepressant medications (%) 13.0 13.9 11.0 12.5 0.4
Cholesterol-lowering medications (%) 43.4 42.9 39.1 35.7 0.006
Values are means or percentages and are standardized to the age distribution of the study
population. *Value is not age adjusted. **P for trends was estimated by general linear model for
means and logistic model for percentages by assigning the median value to each category of
duration of sulfonylurea use and modeling this variable as a continuous variable.
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and 2005, the multivariable-adjusted RRs
of CHD were 1.40 (0.76–2.59) for no-
consistent users and 1.88 (1.09–3.23)
for consistent users of sulfonylureas.
CONCLUSIONS
The primary ﬁnding from this prospective
follow-up of patients with diabetes was
that a longer duration of sulfonylurea
therapy was associated with a higher
risk of CHD. The continuous sulfonylurea
therapy for .10 years was associated
with almost two times greater risk of
CHD compared with nonusers. Further-
more, we observed that the combination
therapy of metformin and sulfonylurea
was associatedwith a three times greater
risk of CHD compared with metformin
monotherapy.
Compared with people without di-
abetes, a two- to fourfold increased risk
of cardiovascular incidence was observed
amongpatientswith type 2diabetes, even
after adjustment for classic risk factors
(28,29). Because cardiovascular risk in-
creases with higher HbA1c levels in people
without diabetes (30), hypoglycemic
treatment may reduce the risk of cardio-
vascular morbidity and mortality among
patients with diabetes. However, the po-
tential cardiovascular beneﬁts through re-
ducing hyperglycemia using sulfonylureas
are complicated by their side effects on
cardiovascular risk (4,15,16,18). The po-
tential reasons for adverse cardiovascular
effects, as previously proposed (3,5,31,32),
include its effect on myocardial ischemic
preconditioning (32), hypoglycemia (5),
weight gain (3), and hypertension (31).
Mechanistically, the sulfonylureas bind to
ATP-sensitive potassium (KATP) channels
on pancreatic b-cells, which results in the
subsequent opening of voltage-gated
calcium channels that stimulate the
movement of insulin-containing secretory
granules from the b-cells into the circula-
tion (32). However, sulfonylureas target
not only pancreatic but also myocardial
KATP channels and therefore may inter-
fere with the cellular pathway that con-
fers myocardial ischemic protection
(33). Sulfonylurea-induced hypoglyce-
mia may also contribute to the increased
risk of cardiovascular disease events and
mortality (34,35). A recent meta-analysis
of clinical trials indicated that the likeli-
hood of hypoglycemia associated with
sulfonylurea treatment was 14 times
greater compared with metformin treat-
ment and 6 times greater compared with
placebo or no therapy (5). In addition,
compared with themetformin users, sul-
fonylurea users experienced a 3–5-kg
more weight gain (3) and 1.2-mmHg in-
crease in systolic blood pressure (31).
Table 2—Risk of incident cardiovascular diseases during 5–10 years of follow-up according to current use of sulfonylurea
Duration of sulfonylurea (years) Yes vs. no
No 1–5 6–10 .10 P for trends RR (95% CI), P
Total cardiovascular disease
Person-years 14,399 11,996 4,438 2,924 19,358 vs. 14,399
Number of cases 122 126 51 40 217 vs. 122
Incident rate
(per 105 person-years) 847 1,050 1,149 1,368 1,121 vs. 847
Adjusted RR (95% CI)
Model 1 Ref 1.25 (0.97–1.61) 1.37 (0.98–1.90) 1.61 (1.12–2.31) 0.006 1.33 (1.07–1.67), P = 0.01
Model 2 Ref 1.25 (0.97–1.62) 1.36 (0.98–1.90) 1.60 (1.11–2.30) 0.007 1.33 (1.06–1.67), P = 0.01
Model 3 Ref 1.20 (0.91–1.58) 1.39 (0.98–1.98) 1.64 (1.11–2.40) 0.007 1.31 (1.01–1.68), P = 0.04
Model 4 Ref 1.20 (0.91–1.58) 1.40 (0.98–1.99) 1.65 (1.12–2.43) 0.007 1.31 (1.01–1.68), P = 0.04
CHD
Number of cases 62 72 30 27 129 vs. 62
Incident rate
(per 105 person-years) 431 600 676 923 666 vs. 431
Adjusted RR (95% CI)
Model 1 Ref 1.40 (0.99–1.97) 1.55 (1.00–2.40) 2.15 (1.36–3.39) 0.001 1.55 (1.14–2.10), P = 0.005
Model 2 Ref 1.37 (0.97–1.94) 1.52 (0.97–2.36) 2.10 (1.32–3.34) 0.002 1.51 (1.11–2.06), P = 0.009
Model 3 Ref 1.24 (0.85–1.81) 1.50 (0.94–2.40) 2.08 (1.27–3.39) 0.003 1.41 (1.01–1.99), P = 0.047
Model 4 Ref 1.24 (0.85–1.81) 1.51 (0.94–2.42) 2.15 (1.31–3.54) 0.002 1.42 (1.01–2.00), P = 0.04
Stroke
Number of cases 60 54 21 13 88 vs. 60
Incident rate
(per 105 person-years) 417 450 473 445 455 vs. 417
Adjusted RR (95% CI)
Model 1 Ref 1.10 (0.76–1.60) 1.17 (0.70–1.93) 1.05 (0.57–1.93) 0.70 1.11 (0.79–1.55), P = 0.54
Model 2 Ref 1.13 (0.78–1.66) 1.17 (0.70–1.95) 1.07 (0.58–1.98) 0.68 1.13 (0.81–1.59), P = 0.47
Model 3 Ref 1.19 (0.78–1.80) 1.29 (0.75–2.21) 1.21 (0.63–2.30) 0.43 1.21 (0.83–1.77), P = 0.32
Model 4 Ref 1.19 (0.79–1.81) 1.29 (0.75–2.20) 1.19 (0.62–2.27) 0.46 1.21 (0.83–1.77), P = 0.32
RR and 95% CIs were estimated from Cox proportional hazards models. Model 1: adjusted age (months). Model 2: further adjusted BMI (kg/m2);
physical activity (quintiles); smoking status (never smoker, former smoker, or current smoker: 1–14 or $15 cigarettes/day); alcohol drinking (0,
0.1–9.9, 10.0–19.9, 20.0–29.9, and$30 g/day); alternative healthy eating index (quintile); Caucasian ethnicity (yes/no); multivitamin use (yes/no);
family history of myocardial infarction (yes/no); family history of stroke (yes/no); presence of hypertension, hypercholesterolemia, and cancer;
self-reported history of coronary artery bypass graft; and regular use of aspirin, antidepressant, antihypertensive, and cholesterol-lowering drugs
(yes/no). Model 3: further adjusted plasma levels of HbA1c (missing and,7, 7–7.9, 8–9.9, 10–11.9, and$12); duration of retina (not affected and
,2, 2–5, and.6 years); duration of kidney disease (not affected and,2, 2–5, and.6 years); duration of neuropathy (nerve damage: not affected
and,2, 2–5, 6–9, 10–14, and$15 years); and use of other diabetic medications including insulin, rosiglitazone, pioglitazone, acarbose, and other
diabetic medications (past, never, and current users for each). Model 4: further adjusted for duration of diabetes (years). Ref, reference.
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Ourﬁnding on the associationbetween
sulfonylurea and CHD is consistent with
previous reports from retrospective ob-
servational studies (15,16,19,36). A re-
cent meta-analysis of observational
studies indicated a 20% higher risk of
myocardial infarction among sulfonyl-
urea users compared with sulfonylurea
nonusers (36). Using the national Veter-
ans Health Administration data linked
to Medicare ﬁles, sulfonylurea users
experienced a higher risk of composite
outcome of hospitalization for acute
myocardial infarction or stroke or death
compared with metformin users (15). In
another study from the U.K. (16), the
association between sulfonylurea and in-
cident acute myocardial infarction was
not signiﬁcant (hazard ratio 1.09 [95%
CI 0.94–1.27]) (16), but they reported
an increased all-cause mortality when
comparing sulfonylurea to metformin
users (16). Another retrospective study
(19) using administrative data from
Saskatchewan Health observed a dose-
response relationship between sulfonyl-
urea drugs andmortality in type 2 diabetic
patients. Although we did not collect the
dosage of sulfonylureas, we observed
that the risk of CHD increased with the
duration of sulfonylurea treatment (i.e.,
the risk was doubled among those using
sulfonylurea for .10 years).
Whenwe classiﬁed the participants ac-
cording to their antihyperglycemic medi-
cations, patients being treated with the
combination of metformin and sulfonyl-
urea had three times higher likelihood of
CHD compared with metformin mono-
therapy. Although the mechanism for
the synergistic effect betweenmetformin
and sulfonylurea is unclear, patients on
the combination therapy had previously
been shown to have a higher risk of total
and cardiovascular mortality in a clinical
trial and several observational studies
(11–13,37).
The strengths of the current study in-
clude its prospective study design, long-
term follow-up, validated cardiovascular
outcome usingmedical records, relatively
large sample size, and data on important
potential confounders including obesity,
diet, and other cardiovascular risk factors.
Our study also has several limitations.
First, as with any observational study,
the possibility of confounding by indica-
tion could not be excluded because the
allocation to a diabetic medication was
not randomized. We attempted to limit
confounding by adjusting the estimates
for many potential risk factors and by
accounting for time-varying covariates.
We also used the propensity score
stratiﬁcationmethod to adjust for differ-
ences across groups, and the results
of sulfonylurea treatment remained
largely unchanged, although the results
between insulin treatment versus met-
formin monotherapy was largely atten-
uated. As demonstrated by Rosenbaum
and Rubin (26), stratifying on the quin-
tiles of the estimated propensity score
eliminated ;90% of the bias due to the
measured confounders. Second, although
our multivariable analysis controlled for a
wide range of risk factors for diabetes,
unmeasured confounding may still exist.
However, only a very strong unmeasured
risk factor for cardiovascular disease to-
getherwith a very large prevalence imbal-
ance among exposure groups could
explain our ﬁndings (38). We estimated
that an unmeasured confounder or an
underreported confounder with a risk
for CHD of 1.5 would need to have a
very large prevalence imbalance to ex-
plain our ﬁndings (39). A stronger con-
founder with a risk for CHD equal to 2.0
would need to be less imbalanced (but
still ;36% more common among sulfo-
nylurea users above 10 years) to explain
our results (39). Third, ourparticipantswere
older women with long-term diabetes. In a
10-year post-interventional follow-up of
the UKPDS participants (40), intensive
therapy with sulfonylurea-insulin combi-
nation in patients with newly diagnosed
type 2 diabetes was associated a signiﬁ-
cant reduction in myocardial infarction
and death from any cause. However, par-
ticipants in the UKPDS study were ;10
years younger than our study population.
Therefore, whether the association be-
tween sulfonylurea therapy and CHD is
only present among patients with in-
creased cardiovascular risk warrants fur-
ther studies in a younger population with
newly diagnosed type 2 diabetes. Fourth,
our cohorts included mostly Caucasian
women who were relatively healthy;
thus, these associations may not be gen-
eralizable to other populations such as
men and other ethnic groups. However,
the relative homogeneity of our study pop-
ulation in terms of educational attainment
and socioeconomic status reduces con-
founding and enhances the internal valid-
ity. The lack of information regarding
the subtype and dosage of sulfonylurea
treatments was also a limitation of our
study. Previous studies reported different
associations with cardiovascular and all-
cause mortality between the ﬁrst- and
second-generation sulfonylureas (3). Fur-
ther studies of different types of sulfony-
lureas on incident CHD are warranted.
In conclusion, our study suggests
that a longer duration of sulfonylurea
therapy was associated with a higher
risk of CHD, and the combination ther-
apy of metformin and sulfonylurea was
associated with an increased CHD risk
compared with metformin monother-
apy or sulfonylurea monotherapy. Fur-
ther prospective cohort studies are
warranted to replicate our ﬁndings.
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